HRC Calls on NY Attorney General to Investigate Turing Pharmaceuticals’ Exploitative Price Gouging

WASHINGTON – Today, the Human Rights Campaign, (HRC), the nation's largest lesbian, gay, bisexual and transgender (LGBT) civil rights organization sent a letter to New York Attorney General Eric Schneiderman asking him to investigate recent actions by New York-based Turing Pharmaceuticals to increase the price of the drug Daraprim (pyrimethamine) by 5000 percent.

“The burden of this unjustified and unprecedented cost will undoubtedly be shouldered by the most vulnerable members of our community -- including people living with HIV and pregnant women,” said HRC President Chad Griffin. “A thorough investigation is needed to determine whether the irresponsible and shameless price increases by Turing Pharmaceuticals is consistent with New York state law.”

View the letter HERE.

NBC News reported yesterday that Martin Shkreli, CEO of Turing Pharmaceuticals, said he will lower the price of Daraprim, but has not specified what the new price will be.

Griffin added, "The world is watching. Those whose lives hang in the balance deserve to know: what will the price of Daraprim betomorrow?"

The Huffington Post reported late yesterday that Shkreli is already involved in a federal criminal investigation dating back to his work with a prior biotechnology company that he founded.

The Human Rights Campaign is America’s largest civil rights organization working to achieve lesbian, gay, bisexual and transgender equality. HRC envisions a world where LGBT people are embraced as full members of society at home, at work and in every community.

###

Contact Us

To make a general inquiry, please visit our contact page. Members of the media can reach our press office at: (202) 572-8968 or email press@hrc.org.